Curovir

Executive Summary

Curovir AB is a Swedish biopharmaceutical company focused on developing novel broad-spectrum antiviral therapies for enterovirus (EV) infections. Enteroviruses are a significant cause of various diseases, including respiratory infections, hand-foot-and-mouth disease, and exacerbations of chronic conditions like COPD. Despite the high medical need, no approved antiviral drug specifically targets EV infections, representing a major treatment gap. Curovir's mission is to address this unmet need by advancing a pipeline of small-molecule antivirals with the potential to become the first registered EV antiviral. The company's approach leverages proprietary chemistry to inhibit viral replication across multiple EV serotypes, offering a broad-spectrum solution. As a private company founded in 2019, Curovir is in preclinical or early clinical stages, with a focus on generating proof-of-concept data to support future clinical development and partnerships. Given the large addressable market and lack of competition, Curovir represents a high-risk, high-reward opportunity in the infectious disease space.

Upcoming Catalysts (preview)

• Q3 2026Preclinical Proof-of-Concept Data for Lead Compound40% success
• Q1 2027IND-Enabling Studies Initiation50% success
• Q4 2026Partnership or Licensing Deal for Enterovirus Program30% success